Novartis Reports Results of Beovu (brolucizumab) in P-III KITE & KINGFISHER Trials for the Treatment of Diabetic Macular Edema

August 18, 2021 Auto Bot Beovu, Clinical Trials, Kite, Novartis, P-III 0

Shots:

  • The company reported 2yrs. & 1 yrs. results from P-III KITE & KINGFISHER studies evaluating Beovu (6mg, q4w) vs aflibercept (2mg) in 926 patients with DME across 36 countries
  • The results showed non-inferiority to aflibercept in a change in BCVA from baseline @100wks. in KITE & 52wks. in KINGFISHER studies. The therapy also demonstrated superior reductions in CSFT & number of eyes with IRF/SRF & was well-tolerated in both studies
  • The company has submitted the applications to FDA and the EMA for Beovu to treat DME and plans to submit applications in other regulatory bodies. The 2yrs. results from the P-III KESTREL trial are expected in Q4’21

Click here to­ read full press release/ article | Ref: Novartis | Image: Reuters

The post Novartis Reports Results of Beovu (brolucizumab) in P-III KITE & KINGFISHER Trials for the Treatment of Diabetic Macular Edema first appeared on PharmaShots.